BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Institute of Biomedical Engineering (BME) - ECPv6.17.4.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Institute of Biomedical Engineering (BME)
X-ORIGINAL-URL:https://bme.utoronto.ca
X-WR-CALDESC:Events for Institute of Biomedical Engineering (BME)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221207T110000
DTEND;TZID=America/Toronto:20221207T120000
DTSTAMP:20221121T210335Z
CREATED:20221121T210335Z
LAST-MODIFIED:20221121T210335Z
UID:10000159-1670410800-1670414400@bme.utoronto.ca
SUMMARY:TBEP Research Seminar: Defining the cardiac fibroblast and its role in health and disease
DESCRIPTION:Jeffery Molkentin\, Ph.D.\nDivision Director of Molecular Cardiovascular Biology and Heart Institute Co-Director\, Cincinnati Children’s Hospital \nProfessor of Pediatrics\, University of Cincinnati Children’s Hospital Medical Center \nRegister for the seminar via Zoom \nAbstract: Collagen production in the adult heart is primarily mediated by the tissue resident interstitial fibroblast. Indeed\, adult fibroblast-specific deletion of the molecular chaperones required for procollagen biosynthesis\, heat-shock protein 47 (Hsp47)\, prevents new fibrillar collagen production in the adult heart. More specifically\, myofibroblast-specific ablation of Hsp47 blocked fibrosis and deposition of collagens type-I\, -III and -V following pressure overload\, which unexpectedly significantly reduced cardiac hypertrophy. These results suggested that an inability to generate new supportive ECM material by cardiac fibroblasts in response to pressure overload was sensed by the cardiomyocyte as it attempted to hypertrophy. To examine this potential mechanism further we also generated Col1a2-loxP targeted mice so that fibroblast specific deletion could be performed to then examine the hypothesis that reduced structural rigor of the newly synthesized type I fibrillar collagen network in the pressure loaded mouse heart would not support the same degree of cardiac hypertrophy. Indeed\, myofibroblast- specific deletion of Col1a2 in the adult heart following 1 week of pressure overload compromised the hypertrophic response. Importantly\, deletion of Col1a2 from the heart resulted in reduced stiffness and structural integrity\, at both baseline with developmental deletion as well as in the adult heart with inducible deletion. Unexpectedly\, developmental deletion of Col1a2 from the mouse heart resulted in a secondary fibrotic response with increased fibroblast number\, which is likely a compensatory response to the decreased stiffness of the ECM due to defective type I collagen. Collectively our results suggest that the cardiac fibroblast communicates with the cardiomyocyte in the heart through the integrity of the ECM\, which also effects fibroblast dynamics.
URL:https://bme.utoronto.ca/event/tbep-research-seminar-defining-the-cardiac-fibroblast-and-its-role-in-health-and-disease/
CATEGORIES:External Speaker Series
ORGANIZER;CN="Translational Biology and Engineering Program (TBEP)":MAILTO:reception.tbep@utoronto.ca
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221207T120000
DTEND;TZID=America/Toronto:20221207T123000
DTSTAMP:20221206T193754Z
CREATED:20220913T210754Z
LAST-MODIFIED:20221206T193754Z
UID:10000113-1670414400-1670416200@bme.utoronto.ca
SUMMARY:Graduate Seminar Series: Clinical Stream - Bonnie Chao
DESCRIPTION:Graduate Seminar Series: Clinical Stream\nGraduate Seminar Series for the Institute of Biomedical Engineering (BME). This day is for clinical stream presenters.\nIf you would like to invite your Principal Investigator\, please add their email via the ‘Add Guest’ button and they will also be notified of your presentation.\nPresentation Title: TBA\nAbstract: TBA\nSupervisor Name: Dr. Shaf Keshavjee\nYear of Study: 4\nProgram of Study: PhD\nZoom link: https://us02web.zoom.us/j/89610372821?pwd=azd4SCtYVWtreVovaGNPV1c2NGY2Zz09\nMeeting ID: 896 1037 2821\nPassword: 483329\nPowered by Calendly.com
URL:https://bme.utoronto.ca/event/graduate-seminar-series-clinical-stream-bonnie-chao/
CATEGORIES:Graduate Seminar Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221207T123000
DTEND;TZID=America/Toronto:20221207T130000
DTSTAMP:20221206T193754Z
CREATED:20220831T170758Z
LAST-MODIFIED:20221206T193754Z
UID:10000085-1670416200-1670418000@bme.utoronto.ca
SUMMARY:Graduate Seminar Series: Clinical Stream - Seyed-Youns Sadat-Nejad
DESCRIPTION:Graduate Seminar Series: Clinical Stream\nGraduate Seminar Series for the Institute of Biomedical Engineering (BME). This day is for clinical stream presenters.\nIf you would like to invite your Principal Investigator\, please add their email via the ‘Add Guest’ button and they will also be notified of your presentation.\nPresentation Title: Challenging the Labels of Autism and ADHD – A Data-Driven Graph-Based Approach\nAbstract: More than 600\,000 children in Canada are diagnosed with autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). These diagnoses are currently based on specific behaviours (e.g.\, social communication difficulties\, inattention)\, which may not correspond to the distinct and unique underlying biology. Moreover\, the labels of ASD and ADHD often do not predict a child’s response to a specific treatment. Instead\, care decisions are made based on each child’s unique behavioural presentation. In many cases\, existing treatments are not effective\, can have adverse side-effects\, and many children continue to experience significant distress and often have poor outcomes as adults (e.g.\, mental health\, employment\, and independence). Collectively\, these challenges suggest that ASD and ADHD may not exist as uniquely-defined diagnostic constructs and highlight the need to discover other groupings that may be more closely aligned with biology and/or response to treatment. To address this need\, the proposed project will perform a data-driven approach to question the validity of current diagnostic labels and identify new groupings for children with ASD and ADHD that are biologically relevant. I will do this through an interdisciplinary approach that employs computer science-based machine learning approaches to go beyond traditional analytics methods in this field. The objective of this project is to validate existing groupings or discover new groupings based on unique and distinct biological data. To this end\, I will pursue a novel analytical approach: instead of comparing diagnostic groups as currently done\, I use an innovative data-driven approach that looks to the data to discover new groups that transcend the existing diagnostic labels or those that validate the current groups but that also explain why the current treatments are ineffective for many individuals in part because of their adverse side effects. I will do this by use of graph clustering method and graph neural network. This approach is capable of identifying groups who share similar neuroanatomical characteristics/complexities\, regardless of diagnosis.\nSupervisor Name: Dr.Azadeh Kushki\nYear of Study: 4\nProgram of Study: PhD\nZoom link: https://us02web.zoom.us/j/89610372821?pwd=azd4SCtYVWtreVovaGNPV1c2NGY2Zz09\nMeeting ID: 896 1037 2821\nPassword: 483329\nPowered by Calendly.com
URL:https://bme.utoronto.ca/event/graduate-seminar-series-clinical-stream-seyed-youns-sadat-nejad/
CATEGORIES:Graduate Seminar Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221207T140000
DTEND;TZID=America/Toronto:20221207T150000
DTSTAMP:20221103T143044Z
CREATED:20221103T143044Z
LAST-MODIFIED:20221103T143044Z
UID:10000155-1670421600-1670425200@bme.utoronto.ca
SUMMARY:The Future of Drug Development through Companion Diagnostics and Therapeutics approaches
DESCRIPTION:The Future of Drug Development through Companion Diagnostics and Therapeutics approaches \nNathan Yoganathan\, President & Chief Scientific Officer \nJN Nova Pharma Inc.  (more info) https://jnnova.com/ \nWednesday\, December 7\, 2022 \nRS 207: 2:00-3:00 PM \nRosebrugh Building (RS): 164 College St\, Toronto\, ON M5S 3E2\nhttps://goo.gl/maps/bVujArG4VdA7MHEo7 \nAbstract:  Dr. Nathan Yoganathan\, President & CSO of JN Nova Pharma (will be presenting their novel technology. JN Nova is a pre-clinical-stage biopharmaceutical company\, focused on efficiently developing innovative treatments that address significant unmet medical needs. JN Nova’s lead product candidate\, JN2019 is a novel anti-COVID-19 molecule. The company is collaborating with Canadian Government labs and Canadian academic centers to accelerate its COVID-19 therapeutic development. This proprietary drug class blocks pan-COVID infection from all variants\, with important renal\, cardiovascular\, and pulmonary protective properties. The lead therapeutic molecules are corona-viral neutralizing agents which trap and inhibit viral entry to the lungs via an enhanced ACE2 enzymatic decoy and cause viral clearance via immunological conjugation and have full ACE2 enzyme replacement activity\, supporting protection from acute kidney injury and enhanced recovery from the acute respiratory syndrome in ICU settings.  Extremely potent vs emergent viral variants: drugs will be developed as accessible\, rapidly administered therapeutic interventions in symptomatic pre-hospitalized and early symptomatic hospitalized patients for people that are infected by these vaccine-escape mutants\, such as Delta\, Omicron\, and beyond. \nThe Institute for Advanced Non-Destructive and Non-Invasive Diagnostic Technologies (IANDIT) in the Faculty of Applied Science and Engineering presents its inaugural guest speaker seminar series with Dr Nathan Yoganathan. The IANDIT  seminar series features leading experts in Non-Destructive Evaluation (NDE) and Non-Invasive Bio-diagnostics (NIB) research in manufacturing industry and healthcare sector in Ontario and beyond. \nJN Nova is interested in collaborating with UofT scientists and engineers to develop non-invasive COVID-19 related technologies including detection and treatment.  \nInterested members of the U of T community who would like to attend the seminars and meet the speaker can email to iandit@mie.utoronto.ca. \nBiography \nDr. T. Nathan Yoganathan is currently the President and Chief Scientific Officer of JN Nova Pharma Inc. Dr. Yoganathan is a university and industrial research scientist\, turned entrepreneur who became an experienced CEO\, having successfully launched several private and a public biotechnology companies. He has over twenty-five years of experience in scientific research in cell signaling and gene expression technology and instrumentation\, has published several articles\, and is an inventor of many patents. \nDr. Yoganathan is the recipient of numerous awards\, including from the Natural Sciences and Engineering Research Council of Canada\, and the Thyroid Foundation of Canada. He serves on a number of advisory boards for both government and industry\, including the CIHR Strategic Training Program in the Bioinformatics Advisory Board\, BIOTE Canada’s Emerging Companies Advisory Board\, and past member of the Ontario Research Fund Advisory Board. He was elected as a Fellow of the Royal Society of Biology. Dr. Yoganathan was a faculty member of the Department of Medicine at the University of Toronto\, and was affiliated with the Lunenfeld and Tanenbaum Research Institute of Mount Sinai Hospital. He holds a B.Sc. (Honours) from the University of North London\, a M.Sc. from the University of Sussex\, and a Ph.D. from the University of Oslo.
URL:https://bme.utoronto.ca/event/the-future-of-drug-development-through-companion-diagnostics-and-therapeutics-approaches/
LOCATION:RS207\, 164 College St\, Toronto\, Ontario\, M5S 3E2\, Canada
CATEGORIES:External Speaker Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221208T120000
DTEND;TZID=America/Toronto:20221208T123000
DTSTAMP:20221207T193728Z
CREATED:20220829T170757Z
LAST-MODIFIED:20221207T193728Z
UID:10000077-1670500800-1670502600@bme.utoronto.ca
SUMMARY:Graduate Seminar Series: Cell and Tissue Stream - Lauren Banh
DESCRIPTION:Graduate Seminar Series: Cell and Tissue Stream\nGraduate Seminar Series for the Institute of Biomedical Engineering (BME). This day is for cell and tissue stream presenters.\nIf you would like to invite your Principal Investigator\, please add their email via the ‘Add Guest’ button and they will also be notified of your presentation.\nPresentation Title: Joint-on-a-chip: advanced in vitro models to recapitulate the osteoarthritic knee joint with microfluidic organ-on-a-chip technology\nAbstract: The “joint-on-a-chip” (JOC) model is an instrumental tool for assessing human-relevant drug responses to novel osteoarthritis (OA) therapies. OA is a whole-joint disease presenting with chronic pain. Symptom management approaches are commonly used as treatment options\, but invasive joint replacement surgery is eventually required because there is currently no cure for OA. The lack of effective therapies is partially due to the absence of experimental models that replicate the complex human joint pathology\, dynamics\, and immune cellular responses. Therefore\, our objective is to develop a novel microfluidic cell culture platform referred to as a “JOC” that provides a more physiologically relevant model of the human joint. Our proposed JOC builds on our static “joint-on-a-dish” model that captures the importance of incorporating multiple tissue crosstalk with immune cells. It will include multiple joint tissues\, a circulatory immune compartment\, and a diffusional joint space to mimic a pathologically relevant OA joint. The JOC is currently being built in modules that contain human cartilage explant tissue and vascularized synovium tissue on two separate chips. Preliminary results reveal that cartilage explants on-chip have a similar gene expression and extracellular matrix degradation profile to the joint-on-a-dish model and that a vascular network forms on-chip by day three of culture. Ongoing experiments are being conducted to combine the modules with various components. Once all components are integrated\, our JOC model will allow for the elucidation of complex mechanisms necessary for targeted drug development and will facilitate the screening of potential therapeutics before entering the clinical setting.\nSupervisor Name: Dr. Sowmya Viswanathan and Dr. Edmond Young\nYear of Study: 2\nProgram of Study: MASc\nZoom link: https://us02web.zoom.us/j/89610372821?pwd=azd4SCtYVWtreVovaGNPV1c2NGY2Zz09\nMeeting ID: 896 1037 2821\nPassword: 483329\nPowered by Calendly.com
URL:https://bme.utoronto.ca/event/graduate-seminar-series-cell-and-tissue-stream-lauren-banh/
CATEGORIES:Graduate Seminar Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221208T120000
DTEND;TZID=America/Toronto:20221208T123000
DTSTAMP:20220829T170757Z
CREATED:20220829T170757Z
LAST-MODIFIED:20220829T170757Z
UID:10000079-1670500800-1670502600@bme.utoronto.ca
SUMMARY:Graduate Seminar Series: Cell and Tissue Stream - Lauren Banh
DESCRIPTION:Graduate Seminar Series: Cell and Tissue Stream\nGraduate Seminar Series for the Institute of Biomedical Engineering (BME). This day is for cell and tissue stream presenters.\nIf you would like to invite your Principal Investigator\, please add their email via the ‘Add Guest’ button and they will also be notified of your presentation.\nPresentation Title: Joint-on-a-chip: advanced in vitro models to recapitulate the osteoarthritic knee joint with microfluidic organ-on-a-chip technology\nAbstract: The “joint-on-a-chip” (JOC) model is an instrumental tool for assessing human-relevant drug responses to novel osteoarthritis (OA) therapies. OA is a whole-joint disease presenting with chronic pain. Symptom management approaches are commonly used as treatment options\, but invasive joint replacement surgery is eventually required because there is currently no cure for OA. The lack of effective therapies is partially due to the absence of experimental models that replicate the complex human joint pathology\, dynamics\, and immune cellular responses. Therefore\, our objective is to develop a novel microfluidic cell culture platform referred to as a “JOC” that provides a more physiologically relevant model of the human joint. Our proposed JOC builds on our static “joint-on-a-dish” model that captures the importance of incorporating multiple tissue crosstalk with immune cells. It will include multiple joint tissues\, a circulatory immune compartment\, and a diffusional joint space to mimic a pathologically relevant OA joint. The JOC is currently being built in modules that contain human cartilage explant tissue and vascularized synovium tissue on two separate chips. Preliminary results reveal that cartilage explants on-chip have a similar gene expression and extracellular matrix degradation profile to the joint-on-a-dish model and that a vascular network forms on-chip by day three of culture. Ongoing experiments are being conducted to combine the modules with various components. Once all components are integrated\, our JOC model will allow for the elucidation of complex mechanisms necessary for targeted drug development and will facilitate the screening of potential therapeutics before entering the clinical setting.\nSupervisor Name: Dr. Sowmya Viswanathan and Dr. Edmond Young\nYear of Study: 2\nProgram of Study: MASc\nZoom link: https://us02web.zoom.us/j/89610372821?pwd=azd4SCtYVWtreVovaGNPV1c2NGY2Zz09\nMeeting ID: 896 1037 2821\nPassword: 483329\nPowered by Calendly.com
URL:https://bme.utoronto.ca/event/graduate-seminar-series-cell-and-tissue-stream-lauren-banh-2/
CATEGORIES:Graduate Seminar Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221209T120000
DTEND;TZID=America/Toronto:20221209T123000
DTSTAMP:20221208T193924Z
CREATED:20220902T172311Z
LAST-MODIFIED:20221208T193924Z
UID:10000092-1670587200-1670589000@bme.utoronto.ca
SUMMARY:Graduate Seminar Series: Molecular Stream - Ayokunle Lekuti
DESCRIPTION:Graduate Seminar Series: Molecular Stream\nGraduate Seminar Series for the Institute of Biomedical Engineering (BME). This day is for molecular stream presenters.\nIf you would like to invite your Principal Investigator\, please add their email via the ‘Add Guest’ button and they will also be notified of your presentation.\nPresentation Title: TBD\nAbstract: TBD\nSupervisor Name: Dr. Warren Chan\nYear of Study: 3\nProgram of Study: PhD\nZoom link: https://us02web.zoom.us/j/89610372821?pwd=azd4SCtYVWtreVovaGNPV1c2NGY2Zz09\nMeeting ID: 896 1037 2821\nPassword: 483329\nPowered by Calendly.com
URL:https://bme.utoronto.ca/event/graduate-seminar-series-molecular-stream-ayokunle-lekuti/
CATEGORIES:Graduate Seminar Series
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20221209T123000
DTEND;TZID=America/Toronto:20221209T130000
DTSTAMP:20221208T193924Z
CREATED:20220910T180742Z
LAST-MODIFIED:20221208T193924Z
UID:10000105-1670589000-1670590800@bme.utoronto.ca
SUMMARY:Graduate Seminar Series: Molecular Stream - Eric Floro
DESCRIPTION:Graduate Seminar Series: Molecular Stream\nGraduate Seminar Series for the Institute of Biomedical Engineering (BME). This day is for molecular stream presenters.\nIf you would like to invite your Principal Investigator\, please add their email via the ‘Add Guest’ button and they will also be notified of your presentation.\nPresentation Title: Towards a Live-Cell Fluorescent Biosensor to Image Beta-cell Endoplasmic Reticulum Stress\nAbstract: Endoplasmic Reticulum (ER) stress is caused by an accumulation of misfolded proteins. When unmitigated\, it results in metabolic dysfunction and apoptosis\, and is a key mechanism responsible for the progression of beta-cell failure leading to Type 2 Diabetes. In response to protein misfolding\, a transmembrane stress-sensing protein called IRE1α can activate the Unfolded Protein Response (UPR). In the early stages of the UPR\, protein translation is attenuated to allow for refolding and repair. If unsuccessful\, degradation of protein and RNA begins\, and apoptosis may be triggered. To measure the dynamics of ER stress in living beta-cells\, we are developing a genetically encoded sensor based on IRE1α. This sensor uses a fluorescent protein-tagged IRE1α\, which homo-oligomerizes to dimeric and tetrameric conformations under early and chronic ER stress\, respectively. These conformational changes can be quantified through changes in the fluorescent polarization ratio of the sensor. To validate this sensor\, we have demonstrated the sensor responds to chemical and physiological (high glucose) stress induction in a rat beta-cell line (INS-1E) and mouse islets. Preliminary data suggest that UPR-associated XBP1 mRNA splicing is highly correlated with sensor response. Furthermore\, individual cells with the highest sensor response (correlating to late-stage UPR) show elevated levels of pro-apoptotic protein TXNIP. These data are consistent with a working sensor that can be used to investigate ER stress dynamics in beta-cells.\nSupervisor Name: Jonathan Rocheleau\nYear of Study: 2\nProgram of Study: PhD\nZoom link: https://us02web.zoom.us/j/89610372821?pwd=azd4SCtYVWtreVovaGNPV1c2NGY2Zz09\nMeeting ID: 896 1037 2821\nPassword: 483329\nPowered by Calendly.com
URL:https://bme.utoronto.ca/event/graduate-seminar-series-molecular-stream-eric-floro/
CATEGORIES:Graduate Seminar Series
END:VEVENT
END:VCALENDAR